Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 18/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.32 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.32 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.32 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3916953 | 0.84 | DHODH (0.38) | DHODHNPSR1NR4A2 | |
| SCHEMBL3925712 | 0.81 | CES2 (0.38) | DHODHNPSR1 | |
| SCHEMBL3926228 | 0.80 | DHODH (0.44) | DHODHNPSR1NR4A2JMJD7NR4A1 | |
| SCHEMBL3917822 | 0.80 | DHODH (0.44) | DHODHNPSR1NR4A2JMJD7NR4A1 | |
| SCHEMBL3918114 | 0.79 | DHODH (0.35) | DHODHNPSR1NR4A2 | |
| SCHEMBL3926127 | 0.78 | DHODH (0.40) | DHODHNPSR1NR4A2JMJD7NR4A1 | |
| SCHEMBL3918117 | 0.73 | DHODH (0.40) | DHODHNPSR1 | |
| SCHEMBL3914244 | 0.73 | NPC1 (0.39) | DHODHNPSR1NR4A2JMJD7NR4A1 | |
| SCHEMBL3914869 | 0.71 | DHODH (0.36) | DHODHNPSR1NR4A2 | |
| SCHEMBL252263 | 0.66 | DHODH (0.45) | DHODHNPSR1PARP1PARP15PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2093214-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2009-08-26 | — | — | EP | disclosed |
| US-7423057-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2008-09-09 | — | — | US | disclosed |
| US-7176241-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-20060199856-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4 SC AG (DE) | 2006-09-07 | — | — | US | disclosed |
| EP-1392642-A2 | NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-20030203951-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2003-10-30 | — | — | US | disclosed |
| WO-2003006425-A2 | NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203951-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | DHODH, DLD, GCDH | DHODH 1/4885NPSR1 4091/4885NR4A2 800/4885 |
| US-20060199856-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | DHODH, DLD, HADHA | DHODH 1/4885NPSR1 3836/4885NR4A2 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.